UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 4,214	$ 3,534
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	155	149
Amortization	1,596	1,646
Provision for losses on accounts receivable	1	8
Operating Lease, Right-of-Use Asset, Amortization Expense	13	14
Deferred income taxes	(3)	(144)
Stock-based compensation expense	50	43
Tax benefit attributable to exercise of stock options	2	0
Changes in operating assets and liabilities
Accounts receivable and other receivables	1,789	(578)
Inventories	(1,084)	(809)
Prepaid expenses and other current assets	25	(109)
Accounts payable	(193)	695
Accrued expenses	350	597
Total adjustments	2,701	1,512
Net cash provided by operating activities	6,915	5,046
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(43)	(237)
Net cash used in investing activities	(43)	(237)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	21	19
Payment of dividends	(1,070)	0
Net cash provided by/(used in) financing activities	(1,049)	19
Effect of exchange rate changes on cash	37	71
Net increase in cash and cash equivalents	5,860	4,899
Cash at beginning of period	75,052	60,974
Cash at end of period	80,912	65,873
Cash paid during the period for income taxes	129	82
Cash paid during the period for interest	$ 0	$ 0